secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELUTIA INC. (ELUT)
CIK:        0001708527
Form:       8-K
Filed at:   2026-08-13T20:15:24+00:00
Accession:  0001104659-26-095934
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elutia secures up to $26M funding, reports Q2 net loss $7.6M; NXT-41x on track
------------------------------------------------------------------------------

- Secured up to $26M: $15M Avenue Capital credit facility and up to $11M from SimpliDerm divestiture; no equity offering.
- Q2 net sales $2.4M (down from $2.7M); net loss $7.6M vs $9.6M; adjusted EBITDA loss $4.6M vs $3.0M.
- Surgeon survey: 86% say current matrices increase infection risk; 96% interested in NXT-41x; 92% would champion at hospital.
- NXT-41 FDA clearance expected 4Q 2026; NXT-41x 1H 2027; commercial launch 2028.
- Cash $19.9M; expects up to $34M additional from signed transactions including $8M BioEnvelope escrow.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708527/000110465926095934/0001104659-26-095934-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708527/000110465926095934/elut-20260813x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-095934

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer